PLYMOUTH
MEETING, Pa., Sept. 1,
2021 /PRNewswire/ -- INOVIO
(NASDAQ:INO), a biotechnology company focused on bringing to
market precisely designed DNA medicines to treat and protect people
from infectious diseases, cancer, and HPV-associated diseases,
today announced that Dr. J. Joseph
Kim, President and CEO, will present at the following
investor conferences in September:
H.C. Wainwright 23rd Annual Global
Investment Conference
Date: September 13-15, 2021
Time:
Recorded presentation will be available on-demand
Presentation Format: Fireside Chat
Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit
Date: Tuesday,
September 21, 2021
Time: 9:55 AM ET
Presentation Format:
Fireside Chat
Cantor Fitzgerald Healthcare Conference
Date: Monday, September 27,
2021
Time: 10:00 AM
ET
Presentation Format: Fireside
Chat
Live and archived versions of the virtual presentations
will be available through the INOVIO Investor Relations Events page
and may be accessed by visiting INOVIO's website at
https://ir.inovio.com/events-and-presentations/default.aspx
. All presentation times are subject to change.
About INOVIO
INOVIO is a biotechnology company focused on rapidly
bringing to market precisely designed DNA medicines to treat and
protect people from infectious diseases, cancer, and diseases
associated with HPV. INOVIO is the first company to have clinically
demonstrated that a DNA medicine can be delivered directly into
cells in the body via a proprietary smart device to produce a
robust and tolerable immune response. Specifically, INOVIO's lead
candidate VGX-3100 met primary and secondary endpoints for all
evaluable subjects in REVEAL 1, the first of two,
Phase 3 trials for precancerous cervical dysplasia, demonstrating
ability to destroy and clear both high-grade cervical lesions and
the underlying high-risk HPV-16/18. INOVIO is also evaluating
INO-4800, a DNA vaccine candidate against COVID-19, in a global
Phase 3 clinical trial, as well as Phase 2 trials in China and South
Korea.
Partners and collaborators include Advaccine, ApolloBio
Corporation, AstraZeneca, The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced
Research Projects Agency/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense/Department
of Defense, HIV Vaccines Trial Network, International Vaccine
Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium,
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
the Parker Institute for Cancer Immunotherapy, Plumbline Life
Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher
Scientific, University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute.
For more information, visit
www.inovio.com.
CONTACTS:
Media: Jeff Richardson,
267-440-4211, jrichardson@inovio.com
Investors:
Ben Matone, 484-362-0076,
ben.matone@inovio.com
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
DNA medicines, our plans and expectations regarding manufacturing,
our plans regarding development of an in-vitro diagnostic, our
expectations regarding our research and development programs,
including the planned initiation and conduct of preclinical studies
and clinical trials and the availability and timing of data from
those studies and trials, and our ability to successfully
manufacture and produce large quantities of our product candidates
if they receive regulatory approval. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, the structuring, initiation and outcomes of clinical
trials, product development programs and commercialization
activities and outcomes, our ability to secure sufficient
manufacturing capacity to mass produce our product candidates, the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA medicines,
our ability to support our pipeline of DNA medicine products, the
ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will
enable us to receive future payments and royalties, the adequacy of
our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted
by us or our collaborators, including alternatives that may be more
efficacious or cost effective than any therapy or treatment that we
and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
we can finance or devote other significant resources that may be
necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2020, our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings we make from time
to time with the Securities and Exchange Commission. There can be
no assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
View original
content:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-investor-conferences-in-september-301367055.html
SOURCE INOVIO Pharmaceuticals, Inc.